Key result
XV454 is a potent, selective platelet GPIIb/IIIa antagonist with high affinity and a slow dissociation rate, providing long-lasting antiplatelet efficacy in non-human primates.
Why the study?
Does XV454 inhibit platelet aggregation and demonstrate favorable binding kinetics compared to c7E3 in preclinical models?
Population
Human, baboon, and canine platelets (in vitro); non-human primates (in vivo)
Comparison
XV454 and XV454 methyl ester pro-drug vs c7E3 (in vitro)
Design
Preclinical
Follow-up
< or = 72 h (in vivo)
Authors
Loading...
XV454's primate data support further preclinical development; leaves open clinical translation and comparison to c7E3.
Does XV454 inhibit platelet aggregation and demonstrate favorable binding kinetics compared to c7E3 in preclinical models?
XV454 is a potent, highly selective platelet GPIIb/IIIa antagonist with high affinity and slow dissociation, providing long-lasting antiplatelet efficacy in preclinical models.
Mousa et al. (1998) studied this question. XV454 vs. c7E3 was evaluated on Platelet aggregation inhibition and binding affinity. XV454 is a potent, selective platelet GPIIb/IIIa antagonist with high affinity and a slow dissociation rate, providing long-lasting antiplatelet efficacy in non-human primates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: